PEOPLE - Helicos BioSciences makes appointment:
This article was originally published in Clinica
Executive Summary
Lifescience company Helicos BioSciences (Cambridge, Massachusetts) has announced interim appointments in response to the resignation of Louise Mawhinney, senior vice-president and CFO. President and COO Steve Lombardi will step in as principal financial officer, while Kevin Lafond, the firm's controller, will stand in as principal accounting officer. Ms Mawhinney has left the firm to pursue other interests. Helicos' proprietary genetic analysis technology is designed to be used across the diagnostics, research and drug discovery markets.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.